Benzinga | Mar 9, 2021 09:16AM EST

Raymond James Downgrades ACADIA Pharmaceuticals to Outperform, Lowers Price Target to $35

Raymond James analyst Danielle Brill downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Strong Buy to Outperform and lowers the price target from $65 to $35.